TuHURA Biosciences And Kintara Therapeutics Announce Agreement For Potential Acquisition Of Kineta's Anti-VISTA Antibody
Portfolio Pulse from Benzinga Newsdesk
TuHURA Biosciences and Kintara Therapeutics have announced an agreement for the potential acquisition of Kineta's anti-VISTA antibody, KVA12123. This antibody is currently in Phase 1/Phase 2 clinical trials and has shown a favorable safety profile. Additionally, TuHURA received a $5 million investment from an existing shareholder.
July 08, 2024 | 10:35 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Kineta's anti-VISTA antibody, KVA12123, is being considered for acquisition by TuHURA Biosciences. The antibody is in Phase 1/2 trials and has shown a favorable safety profile.
The potential acquisition of KVA12123 by TuHURA Biosciences could positively impact Kineta's stock due to the promising clinical trial results and the strategic interest from TuHURA.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 80
POSITIVE IMPACT
Kintara Therapeutics is involved in the agreement for the potential acquisition of Kineta's anti-VISTA antibody, KVA12123. This development could enhance Kintara's portfolio and market position.
The agreement for the potential acquisition of KVA12123 could positively impact Kintara Therapeutics by enhancing its portfolio and market position, especially given the promising clinical trial results.
CONFIDENCE 85
IMPORTANCE 60
RELEVANCE 70